Skip to main content
BEIJING LEADMAN BIOCHEMISTRY CO.,LTD. logo

BEIJING LEADMAN BIOCHEMISTRY CO.,LTD. — Investor Relations & Filings

Ticker · 300289 ISIN · CNE100001C22 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,952 across all filing types
Latest filing 2025-10-28 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300289

About BEIJING LEADMAN BIOCHEMISTRY CO.,LTD.

https://www.leadmanbio.com

Beijing Leadman Biochemistry Co., Ltd. specializes in the research, development, manufacturing, and distribution of in-vitro diagnostic (IVD) solutions. The company’s core portfolio includes a wide range of clinical chemistry reagents, chemiluminescence immunoassay kits, and automated diagnostic instruments. These products support various medical testing areas, such as liver and kidney function, lipid profiles, and cardiac markers. By providing integrated systems that combine high-performance reagents with specialized hardware, the company serves hospitals, clinical laboratories, and medical institutions. Its operations focus on delivering precise and efficient diagnostic tools to enhance clinical decision-making and patient care.

Recent filings

Filing Released Lang Actions
关于修订《公司章程》及附件的公告
Governance Information Classification · 95% confidence The document is a detailed announcement from Beijing Lidman Biochemical Co., Ltd. regarding the revision of the company's Articles of Association and related attachments. It includes extensive legal and regulatory references, detailed changes to corporate governance documents, shareholder rights, board responsibilities, and procedural rules. The content focuses on governance structure, board and shareholder meeting procedures, and company bylaws. There is no indication of financial statements, audit opinions, earnings data, or capital market transactions. The document is not a report of financial results or an announcement of voting results but a formal disclosure of governance-related amendments. Therefore, the document best fits the category of Governance Information (CGR). The document length and detail confirm it is the actual governance document, not merely an announcement of its publication.
2025-10-28 Chinese
关于召开2025年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about convening the 2025 first extraordinary general meeting (临时股东大会) of Beijing Leadman Biochemical Co., Ltd. It includes information about the meeting date, voting procedures, proposals to be voted on (such as election of a director and amendment of company articles), registration details, and proxy forms. There is no financial data or report content; rather, it is an announcement and procedural notice for a shareholder meeting. This fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings. The document length is about 4109 characters, which is consistent with a detailed meeting notice rather than a full report. Therefore, the correct classification is PSI.
2025-10-28 Chinese
关于补选董事会提名委员会委员和审计委员会委员的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a board member and the subsequent election of new members to the board's nomination and audit committees. It includes details about the changes in the board composition and committee memberships. There is no financial data, report, or presentation content. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2025-10-28 Chinese
2025年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '北京利德曼生化股份有限公司 2025 年第三季度报告' which translates to 'Beijing Leadman Biochemical Co., Ltd. 2025 Third Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial changes for the third quarter of 2025. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. It also mentions the report is unaudited, which is common for interim/quarterly reports. The length of the document (over 13,000 characters) and the presence of substantive financial data confirm it is the actual report, not just an announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2025
2025-10-28 Chinese
关于补选董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election of a new non-independent director to the company's board. It includes details about the candidate's background, the nomination process, and compliance with regulatory requirements. There is no financial data, earnings information, or report publication mentioned. The content clearly pertains to changes in the company's board of directors. Therefore, this document fits the category of Board/Management Information (MANG). The document length is short and focused solely on this announcement, confirming it is not a full report or other filing type.
2025-10-28 Chinese
第六届董事会第六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Beijing Lidman Biochemical Co., Ltd. It includes details about board committee member appointments, approval of the 2025 third quarter report, amendments to company bylaws, and scheduling of a shareholders meeting. The text explicitly states that the actual 2025 third quarter report is separately disclosed on the cninfo website (announcement number 2025-046). The document itself does not contain the financial statements or substantive financial data of the quarterly report but only the board's approval of it. The document length is 2250 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is an official announcement of board meeting resolutions, including approval of a quarterly report, but not the report itself. This fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. It is not an Interim/Quarterly Report (IR) because it lacks actual financial data, nor is it a Management Report (MDA) or Board/Management Information (MANG) since it covers multiple board resolutions and procedural matters rather than just management changes.
2025-10-28 Chinese

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.